☆ 4.4 Article

Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations

EXPERT REVIEW OF VACCINES (2022)

Related references

Note: Only part of the references are listed.

Review Infectious Diseases

Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature

Marcial Delgado-Fernandez et al.

Summary: This article discusses the use of COVID-19 convalescent plasma (CCP) in patients with humoral immunodeficiency. The study suggests that CCP can improve clinical symptoms and shorten the duration of the disease for patients with congenital primary immunodeficiency or those on treatment with anti CD20 antibodies.

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2022)

Add to Collection

Letter Hematology

Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy

Massimo Franchini et al.

VOX SANGUINIS (2021)

Add to Collection

Article Oncology

Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma

Zachary Wright et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Article Allergy

Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

Isabelle Meyts et al.

Summary: The study shows that patients with IEI exhibit varied responses to SARS-CoV-2 infection, with some requiring hospitalization and even intensive care, and a non-negligible mortality rate. In comparison to the general population, younger IEI patients may face a higher risk of severe illness and mortality.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Ji Hoon Baang et al.

Summary: This case illustrates challenges in managing immunocompromised hosts with chronic COVID-19, who may act as persistent shedders and sources of transmission. The patient's lack of seroconversion and prolonged course highlight the importance of humoral immunity in resolving viral infections.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Treatment of immunocompromised COVID-19 patients with convalescent plasma

Monica Fung et al.

Summary: Convalescent plasma treatment appears to be safe and potentially beneficial for immunosuppressed patients with COVID-19, as evidenced by clinical improvements in patients who received this therapy. Further data is needed to determine the efficacy of convalescent plasma as a primary or adjunctive therapy for COVID-19, especially for immunocompromised patients.

TRANSPLANT INFECTIOUS DISEASE (2021)

Add to Collection

Article Immunology

Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy

Syed Naeem et al.

Summary: COVID-19 is a highly infectious viral disease that can be more severe in patients with underlying medical conditions. This study showed that kidney transplant recipients with COVID-19 could recover after receiving CCP therapy. Further research is needed to explore the clinical outcomes associated with CCP use in this population.

TRANSPLANT INFECTIOUS DISEASE (2021)

Add to Collection

Letter Hematology

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

Albrecht Betrains et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Letter Immunology

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy

Jonathan London et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency

Samaneh Delavari et al.

Summary: A study on patients with primary immunodeficiency disorders showed that while their incidence of infections was only 1.23 times higher than the general population, their mortality rate was 10 times higher, particularly in patients with combined immunodeficiency and immune dysregulation. Further management strategies such as hematopoietic stem cell transplantation and immunomodulatory agents should be considered to improve the survival rate in these patients.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Immunology

COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature

Mohammed A. Raja et al.

Summary: A systematic review and meta-analysis of SOT recipients with SARS-CoV-2 infection revealed a high hospital admission rate and mortality rate. Common symptoms included fever and cough, with the majority of recipients requiring hospital treatment. Use of immunosuppressive medications decreased, while treatments varied.

TRANSPLANTATION REVIEWS (2021)

Add to Collection

Article Immunology

SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency

Nicolai S. C. van Oers et al.

Summary: X-linked severe combined immunodeficiency (X-SCID) is a severe immune disorder caused by genetic mutations, with patients facing opportunistic infections. An infant with X-SCID contracted SARS-CoV-2 before receiving a stem cell transplant, but ultimately recovered after treatment.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Immunology

Fatal SARS-CoV-2 infection in a male patient with Good's syndrome

Maria Rosa Pozzi et al.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Immunology

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma

Aled Iaboni et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Hematology

Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies

Preethi Jeyaraman et al.

Summary: This retrospective multicentre study analyzed the 14-day mortality in 33 patients with hematological malignancies who received convalescent plasma therapy for severe Covid-19. The study found that patients who received plasma therapy early had a shorter duration of hospitalization. The overall mortality rate was 45.5%, with no significant impact of disease status, active therapy, or comorbidities on mortality.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Allergy

Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma

Luciana C. Ribeiro et al.

Summary: This case report highlights the potential of using COVID-19 convalescent donor plasma as a valuable therapeutic approach for patients with common variable immunodeficiency and severe COVID-19. The patient showed rapid improvement after receiving four doses of convalescent plasma over a period of 6 days, with reduction of lung abnormalities and interruption of mechanical ventilation.

ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Biology

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19

Daniele Focosi et al.

Summary: Effective treatments specific for COVID-19 are still lacking, but passive immunotherapies based on neutralizing antibodies have shown potential benefits in early disease course. COVID-19 convalescent plasma and monoclonal antibodies have been granted emergency use authorization, while hyperimmune serum derived from CCP donations or animals immunized with SARS-CoV-2 antigens may be the next nAb-derived candidate.

LIFE-BASEL (2021)

Add to Collection

Article Immunology

Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products

Ariel Kenig et al.

Summary: This study demonstrates the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion, showing significant clinical improvement and rapid viral clearance following plasma administration.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Review Hematology

COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review

Daniele Focosi et al.

Summary: The outbreak of COVID-19 has caused a global health crisis, with convalescent plasma being suggested as a potential treatment option. Research indicates that convalescent plasma may provide greater benefits for COVID-19 patients with humoral immune deficiencies.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Possible COVID-19 reinfection in a patient with X-linked agammaglobulinaemia

Sook Yin Loh et al.

Summary: This report discusses a case of a patient with XLA and bronchiectasis who may have experienced reinfection with COVID-19. Lessons learned include the need for extra caution when providing care for patients with weakened immune systems and the importance of repeating COVID-19 testing.

BMJ CASE REPORTS (2021)

Add to Collection

Article Hematology

SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation

Dmitry Balashov et al.

Summary: A 9-month-old girl with juvenile myelomonocytic leukemia who received HSCT from a haploidentical donor developed bilateral viral pneumonia due to SARS-CoV-2 infection, which was partially resolved with tocilizumab and convalescent plasma therapy. However, complete elimination of the virus was not achieved after 4 months, likely due to persistent immunodeficiency and lack of adaptive immune response post-HSCT. This case highlights the potential effectiveness of convalescent plasma in combination with other therapies for treating COVID-19 in immunocompromised patients.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Immunology

The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019

Lauren Fill et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2020)

Add to Collection

Letter Hematology

Clinical outcome of coronavirus disease 2019 in haemato-oncology patients

James A. Aries et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Allergy

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Isabella Quinti et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Hematology

Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis

Olgu Erkin Cinar et al.

TRANSFUSION AND APHERESIS SCIENCE (2020)

Add to Collection

Article Oncology

COVID-19 in persons with haematological cancers

Wenjuan He et al.

LEUKEMIA (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to SARS-CoV-2 in patients with COVID-19

Quan-Xin Long et al.

NATURE MEDICINE (2020)

Add to Collection

Article Allergy

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

Annarosa Soresina et al.

PEDIATRIC ALLERGY AND IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor?

Fateme Babaha et al.

AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2020)

Add to Collection

Review Microbiology

Convalescent Plasma Therapy for COVID-19: State of the Art

Daniele Focosi et al.

CLINICAL MICROBIOLOGY REVIEWS (2020)

Add to Collection

Letter Surgery

Convalescent plasma therapy: Helpful treatment of COVID-19 in a kidney transplant recipient presenting with serve clinical manifestation and complex complications

Jipin Jiang et al.

CLINICAL TRANSPLANTATION (2020)

Add to Collection

Letter Hematology

Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery

Evangeline Clark et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Letter Allergy

Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma

Estefania Mira et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Article Hematology

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti et al.

LANCET HAEMATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

Michael J. Joyner et al.

MAYO CLINIC PROCEEDINGS (2020)

Add to Collection

Article Hematology

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Thomas Hueso et al.

BLOOD (2020)

Add to Collection

Article Hematology

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma

Ayse Karatas et al.

TRANSFUSION AND APHERESIS SCIENCE (2020)

Add to Collection

Article Immunology

COVID-19 in recent heart transplant recipients: Clinicopathologic features and early outcomes

Brian Lima et al.

TRANSPLANT INFECTIOUS DISEASE (2020)

Add to Collection

Letter Oncology

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

Guido Lancman et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Letter Oncology

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Lindsey E. Roeker et al.

LEUKEMIA (2020)

Add to Collection

Article Oncology

Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients

Douglas Tremblay et al.

CANCER MEDICINE (2020)

Add to Collection

Letter Allergy

Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma

Haoli Jin et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Article Hematology

Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19

Tim Luetkens et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Victoria A. Avanzato et al.

CELL (2020)

Add to Collection

Letter Medicine, General & Internal

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Teresa Aydillo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Infectious Diseases

Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

Ivana Milosevic et al.

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2020)

Add to Collection

Article Medicine, General & Internal

A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma

Joanna L. Moore et al.

AMERICAN JOURNAL OF CASE REPORTS (2020)

Add to Collection

Review Allergy

Enteroviruses in X-Linked Agammaglobulinemia: Update on Epidemiology and Therapy

David Bearden et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.